California-based biotechnology company Anixa Biosciences Inc (NASDAQ: ANIX) announced on Tuesday that the US Food and Drug Administration (FDA) has granted approval to the company's collaborator, Moffitt Cancer Center, for an individual patient Investigational New Drug Application (IND) to allow a second dose of its CAR-T therapy for a patient who may be demonstrating clinical activity to the initial treatment.
Dr Robert Wenham, chair of the Department of Gynecologic Oncology at Moffitt, and the principal investigator for the trial, said: "In the first cohort and at the lowest dose administered, despite an initial increase in tumour size that met criteria for progression, one patient has remained off new therapy for many months with no new disease. Even her tumour marker that was initially elevating later began to fall. A biopsy demonstrated tumour with necrosis, inflammation and T cell infiltration by Immunohistochemistry (IHC). Based on these findings, we sought approval from the FDA to administer a second treatment to her, aiming to increase the likelihood of a partial or complete response. Recently, we received that approval from the FDA."
The Phase I clinical trial at Moffitt is treating recurrent ovarian cancer patients who have failed standard-of-care therapies. To date, six patients have been treated in the dose escalation trial: three in the first cohort and three in the second cohort. Dose escalation will continue after confirming that the previous dosages are safe.
Nektar Therapeutics showcases rezpegaldesleukin at EADV 2024
Priovant Therapeutics enrols first patients in brepocitinib CLARITY study
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
Pfizer names new Regional President for Middle East, Russia and Africa
GSK's Nucala approved in Japan for chronic rhinosinusitis with nasal polyps
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
Lipella launches OLP Patient Registry to advance research
Talphera enrols first subject in NEPHRO CRRT study
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults
Cantargia reports positive CAN10 trial data
Quoin Pharmaceuticals to study QRX003 for Peeling Skin Syndrome
Dragonfly Therapeutics names new chief financial officer
Formosa Pharmaceuticals secures exclusive Canadian licensing deal with Apotex
Bio-Techne invests in Spear Bio to boost ultra-sensitive immunoassay development